| Code | CSB-RA023986MB12HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to HL05, targeting TNFSF11 (Tumor Necrosis Factor Superfamily Member 11), also known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). TNFSF11 is a critical cytokine that regulates bone metabolism by promoting osteoclast differentiation, activation, and survival. This protein plays a central role in skeletal remodeling and calcium homeostasis. Dysregulation of TNFSF11 signaling is implicated in various pathological conditions, including osteoporosis, rheumatoid arthritis, bone metastases, and metabolic bone diseases. The RANKL/RANK/OPG pathway represents a fundamental mechanism in bone biology and immune system regulation.
The reference antibody HL05 has been utilized in research investigating bone metabolism disorders and RANKL-mediated signaling pathways. This biosimilar provides researchers with a valuable tool for studying osteoclastogenesis, bone resorption mechanisms, and the therapeutic potential of RANKL inhibition. It supports investigations into skeletal diseases, tumor-induced bone loss, and immune-bone interactions, facilitating advancement in osteoimmunology research.
There are currently no reviews for this product.